Trial Profile

Clinical Study to Assess Efficacy and Safety of LN-145/LN-145-S1 (Autologous Centrally Manufactured Tumor Infiltrating Lymphocytes) Across Multiple Tumor Types

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine; Ipilimumab; Nivolumab
Indications Carcinoma; Cervical cancer; Chondrosarcoma; Giant cell tumours; Malignant fibrous histiocytoma; Osteosarcoma; Ovarian cancer; Sarcoma; Soft tissue sarcoma; Thyroid cancer; Triple negative breast cancer
Focus Therapeutic Use
Acronyms Iovance Alliance

Most Recent Events

11 Jun 2025 Planned End Date changed from 30 Jun 2025 to 30 Apr 2027.
11 Jun 2025 Planned primary completion date changed from 30 Jun 2025 to 30 Apr 2027.
16 May 2024 Planned End Date changed from 30 Jun 2024 to 30 Jun 2025.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com